PMC:7195088 / 21747-21926 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"676","span":{"begin":40,"end":48},"obj":"Species"},{"id":"801","span":{"begin":14,"end":24},"obj":"Chemical"},{"id":"942","span":{"begin":54,"end":62},"obj":"Disease"}],"attributes":[{"id":"A676","pred":"tao:has_database_id","subj":"676","obj":"Tax:9606"},{"id":"A801","pred":"tao:has_database_id","subj":"801","obj":"MESH:C000606551"},{"id":"A942","pred":"tao:has_database_id","subj":"942","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T13","span":{"begin":163,"end":168},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T106","span":{"begin":54,"end":62},"obj":"Disease"}],"attributes":[{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T106","span":{"begin":145,"end":148},"obj":"http://purl.obolibrary.org/obo/CLO_0050154"}],"text":"Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T242","span":{"begin":14,"end":24},"obj":"Chemical"}],"attributes":[{"id":"A242","pred":"chebi_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15."}

{"project":"LitCovid-sentences","denotations":[{"id":"T158","span":{"begin":64,"end":107},"obj":"Sentence"},{"id":"T159","span":{"begin":108,"end":179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15."}